Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT02179671 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Interventions

DRUG: Gefitinib
DRUG: AZD9291
DRUG: Selumetinib+Docetaxel
DRUG: Tremelimumab

Sponsor

AstraZeneca

Collaborators

[object Object]